Business Context and Reporting Period
Company: Fortress Biotech, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 19, 2024 (Event Date)
Closing Date: September 23, 2024
Context: The Company announced the entry into material definitive agreements for a registered public offering of common stock and concurrent private placements of common stock and warrants.
Key Financial Metrics and Capital Raise
- Registered Offering Proceeds: Approximately $6.5 million in gross proceeds from the sale of 3,939,394 shares of Common Stock at $1.65 per share.
- Chairman Private Placement Proceeds: Approximately $1.5 million in gross proceeds from the sale of 763,359 shares of Common Stock at $1.84 per share and associated warrants.
- Total Gross Proceeds: Approximately $8.0 million (combined Registered Offering and Private Placements).
- Placement Agent Fees: 7.0% commission on gross proceeds from the Registered Offering and Investor Private Placement; 3.5% commission on proceeds from the Chairman Private Placement (insider sale).
- Other Expenses: $75,000 reimbursed to the Placement Agent for fees and expenses, plus a non-accountable expense allowance up to $10,000.
- Warrant Terms: PIPE Warrants to purchase 4,702,753 shares total (3,939,394 Investor Warrants + 763,359 Chairman Warrants) with an exercise price of $1.84 per share. Warrants become exercisable six months after issuance and expire five and one-half years from issuance.
Material Changes and Use of Proceeds
This filing represents a significant capital event rather than a periodic financial performance report. Consequently, there are no comparative revenue, profit, or margin metrics provided in this document.
Use of Proceeds: The Company intends to use net proceeds for general corporate purposes, including:
- Research and development expenditures.
- Clinical trial expenditures.
- Licensing or acquisition of new products.
- Working capital.
Guidance, Risks, and Contingencies
Management Commentary: The Company highlighted the need for substantial additional funds and uncertainties relating to financings as key factors in its growth strategy.
Lock-Up Agreement: Executive officers, directors, and holders of 5% or more of outstanding shares entered into a lock-up agreement preventing the sale or transfer of securities for 60 days after the Effective Date of the Resale Registration Statement.
Resale Registration: The Company is required to file a resale registration statement by November 3, 2024, to register the resale of shares issuable upon exercise of PIPE Warrants and shares sold in the Chairman Private Placement. This statement must be declared effective within 60 days of closing (or 90 days if reviewed by the SEC).
Risks and Contingencies: Forward-looking statements are subject to risks including:
- Ongoing UTRF litigation and indemnification of Caelum.
- Uncertainties regarding regulatory approvals (FDA).
- Early stage of product development and clinical testing results.
- Ability to secure third-party manufacturing and distribution.
- Intellectual property matters and competition.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7.0% and 3.5% placement agent commissions and the $75,000 expense reimbursement.
- Confirm the effective date of the Resale Registration Statement to determine the exact expiration of the 60-day lock-up period.
- Review the specific terms of the PIPE Warrants (Exhibit 4.1) for anti-dilution adjustments and exercise conditions.
- Monitor the status of the ongoing UTRF litigation mentioned as a material risk factor.
- Check subsequent filings for the actual allocation of funds between R&D, clinical trials, and working capital.